| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:MK-1421
CAS:1235995-16-0
Package:25mg/RMB 12800;100mg/RMB 21500;50mg/RMB 16800
|
1235995-16-0 manufacturers
- MK-1421
-
- $1820.00 / 25mg
-
2025-08-21
- CAS:1235995-16-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 1235995-16-0 Basic information |
| Product Name: | 1235995-16-0 | | Synonyms: | 1,3,4-Oxadiazol-2(3H)-one, 5-[(1R,3R)-1-(1-ethyl-1H-pyrazol-4-yl)-3-[5-(5-fluoro-2-pyridinyl)-1H-imidazol-2-yl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]-3-methyl- | | CAS: | 1235995-16-0 | | MF: | C27H24FN9O2 | | MW: | 525.54 | | EINECS: | | | Product Categories: | | | Mol File: | 1235995-16-0.mol |  |
| | 1235995-16-0 Chemical Properties |
| Boiling point | 794.8±70.0 °C(Predicted) | | density | 1.58±0.1 g/cm3(Predicted) | | pka | 11.66±0.10(Predicted) |
| | 1235995-16-0 Usage And Synthesis |
| Uses | MK-1421 is a potent and selective sstr3 antagonist. MK-1421 regulates insulin secretion by binding to the sstr3. MK-1421 can be used in the research of type 2 diabetes[1]. | | References | [1] Shah S K, et al. Discovery of MK-1421, a potent, selective sstr3 antagonist, as a development candidate for type 2 diabetes[J]. ACS Medicinal Chemistry Letters, 2015, 6(5): 513-517. DOI:10.1021/ml500514w |
| | 1235995-16-0 Preparation Products And Raw materials |
|